This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophonede Cytogenetique Hematologique. Leukemia. 2006;20:696–706.6.
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118:3645–56. https://doi.org/10.1182/blood-2011-04-346643.
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, et al. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014;124:2400–7. https://doi.org/10.1182/blood-2014-04-570929.
Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. Blood. 2020;136:2275–89. https://doi.org/10.1182/blood.2020007093.
Chou W-C, Chen C-Y, Hou H-A, Lin L-I, Tang J-L, Yao M, et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia. 2009;23:1303–10. https://doi.org/10.1038/leu.2009.25.
Shima Y, Yumoto M, Katsumoto T, Kitabayashi I. MLL is essential for NUP98-HOXA9-induced leukemia. Leukemia. 2017;31:2200–10. https://doi.org/10.1038/leu.2017.62.
Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, et al. Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. J Oncol. 2019;2019:1609128. https://doi.org/10.1155/2019/1609128.
Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet. 1996;12:154–8. https://doi.org/10.1038/ng0296-154.
Moore MA, Chung KY, Plasilova M, Schuringa JJ, Shieh JH, Zhou P, et al. NUP98dysregulation in myeloid leukemogenesis. Ann NY Acad Sci. 2007;1106:114–42.
Sun H, Yan H, Yan Z, Zhu Y, Yang G, Zhang S. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT. Ann Hematol. 2023;102:473–5. https://doi.org/10.1007/s00277-022-05047-8.
Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, et al. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia. 2019;33:1360–72. https://doi.org/10.1038/s41375-018-0327-2.
Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139:894–906. https://doi.org/10.1182/blood.2021012806.
Acknowledgements
This work is supported by Tianjin Municipal Science and Technology Commission Grant (21JCZDJC01170), Chinese Academy of Medical Sciences Innovation fund for Medical Sciences (2021-I2M-C&T-B-080, 2021-I2M-1-017), Haihe Laboratory of Cell Ecosystem Innovation Fund(22HHXBSS00036) to SF, Youth Program of National Natural Science Foundation of China 81900182) to YS.
Author information
Authors and Affiliations
Contributions
YS participated in data collection and manuscript writing. TZ, LZ, SZ, ZC collected the data. RL, JW, DY, EJ, SF, YH contributed to treating patients and supervised the study. YH and SF designed and approved the study.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shen, Y., Zhang, T., Zhang, L. et al. Allogeneic stem cell transplantation can prolong the survival of patients with NUP98-rearranged acute myeloid leukemia. Bone Marrow Transplant 58, 1149–1151 (2023). https://doi.org/10.1038/s41409-023-02030-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-02030-3